Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dyskinesia, Feeling abnormal, Heart rate increased, Hyperhidrosis
Clinical narrative: fainted; At 3am I woke up feeling very sore; came to drenched in sweat; felt very heavy; having trouble moving my limbs and holding my head up; experienced palpitations band an elevated heart rate; experienced palpitations band an elevated heart rate; threw up; diarrhea; This is a spontaneous report from a contactable nurse (patient). A 27-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EW0176, expiration date not provided), 2nd dose via an unspecified route of administration, administered in Arm Left on 18May2021 14:15 at age of 27 years old as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS). The patient's concomitant medications were not reported. The patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EW0176, expiration date not provided), 1st dose via an unspecified route of administration, administered in Arm Left on 27Apr2021 14:15 as a single dose for COVID-19 immunisation.  The patient experienced 'fainted, at 3am I woke up feeling very sore, came to drenched in sweat, felt very heavy, having trouble moving her limbs and holding her head up, experienced palpitations band an elevated heart rate, threw up, diarrhea', all on 19May2021 03:00.  At 3am she woke up feeling very sore so she got up and walked to the bathroom to take some Tylenol. Before she could take any she fainted. After it passed she tried to sit up with her back against the wall and fainted again. She came to drenched in sweat and felt very heavy. She was having trouble moving her limbs and holding her head up because they felt too heavy. She also experienced palpitations band an elevated heart rate during this. Then she threw up and had diarrhea. No treatment received. The outcome of the events was recovering. The report was reported as non-serious. The patient was not pregnancy at time of vaccination. The patient had no known allergies. The patient had not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received within 2 weeks of vaccination included oral birth control. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.   Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of event faint cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.